(Press-News.org) Manuel A. Friese, MD, clinician-scientist at the Institute of Neuroimmunology and Multiple Sclerosis of the University Medical Center Hamburg-Eppendorf in Hamburg, Germany was awarded the 2025 Barancik Prize for Innovation in MS Research. He is being recognized for his groundbreaking work studying the interactions between inflammation and nerve cell death (also called neurodegeneration) that drive disease progression. His work has the potential to identify new therapeutic targets for MS. It also brings the field closer to stopping disease progression, a key objective of the Pathways to Cures Research Roadmap.
Previous Barancik Prize winner Peter Calabresi, MD, nominated Friese for the prize, commenting, “Manuel Friese’s work has fundamentally reshaped how we understand neurodegeneration in progressive multiple sclerosis. By bridging immunology, neurobiology, and translation to the clinic, he has opened entirely new therapeutic avenues where few existed before. The Barancik Prize is a fitting recognition of his originality, rigor, and transformative impact on the field.”
With MS, the immune system attacks the brain and spinal cord. During the attack, myelin (the protective coating around nerve cell fibers) and axons (nerve cell fibers) are damaged. Unresolved damage promotes disrupted cell signaling and nerve cell death that leads to MS symptoms, clinical disability accumulation, and disease progression.
Historically, MS research and drug development has focused on the inflammation that causes attacks. Although current disease-modifying therapies effectively suppress the immune response and reduce relapses, they do not prevent disease progression. This treatment gap motivated Friese to study other biological drivers of MS progression.
His research focuses on how nerve cells react to the inflammatory environment seen with MS. His group has led the way in identifying specialized interactions between inflammation and nerve cells, including specific pathways and proteins that could be future therapeutic targets. A selection of Dr. Friese’s many research contributions include:
Characterizing the “neuronal inflammatory stress response:”
Friese discovered that nerve cells are not just passive victims of inflammation, as once believed. Instead, when exposed to inflammatory signals, nerve cells actively respond. They trigger internal pathways that disrupt processes that nerve cells generally need to stay healthy, like protein clearance, metabolism, signaling, and gene regulation. The disruptions lead to nerve cell damage and neurodegeneration.
Genetic or drug-based approaches that target these pathways can help correct the cellular disturbances, preserve nerve cell health, and, in some cases, reduce disease severity in mouse models that have MS-like characteristics.
IMPACT: This work has shifted how scientists think about nerve cell death and MS progression. It has also identified many new potential targets for future treatments that could protect nerve cell health and stop disease progression.
Discovering a new brain-immune connection that reduces MS inflammation:
Friese found that levels of a protein in the bloodstream called GDF-15 increase during pregnancy and are associated with fewer relapses. GDF-15 sends signals to specific neurons in the brainstem that can reprogram the immune system. The reprogramming reduces harmful immune cells from entering the brain and spinal cord and protects against inflammatory insult.
IMPACT: This newly identified brain-immune pathway could be harnessed for future MS therapies. GDF-15-based treatments are already being tested in humans for other conditions, potentially speeding up their advancement to clinical testing for MS.
Speaking about the National MS Society’s award decision, Bruce Bebo, PhD, Executive Vice President of Research at the National MS Society commented, “Dr. Friese’s work exemplifies the kind of bold, innovative science the Barancik Prize was created to recognize. His research provides a new vision for treating MS – one that goes beyond controlling inflammation. His discoveries open promising new paths toward therapies that could finally address neurodegeneration and bring us closer to stopping disease progression – one of the most urgent unmet needs for people living with MS.”
In addition to his laboratory research, Friese remains a leader in the clinic when treating people with MS. Alongside colleagues at the University Medical Center Hamburg-Eppendorf, he is overseeing the first people with progressive MS receiving CD19 CAR-T therapy. This is an experimental approach in the very early stages of clinical testing for MS. It is not yet proven safe or effective for MS, but could one day represent a new type of treatment if larger studies are successful.
Commenting on the award, Friese noted,
"I am deeply honored to receive the Barancik Prize and humbled to join the distinguished group of previous recipients. As a neurologist caring for patients with multiple sclerosis, I am aware of the urgency of uncovering the pathophysiological basis of MS progression. My early integration of neurobiology and immunology has enabled me to pioneer mechanistic insights into how nerve cells respond to and are reprogrammed by inflammation during MS. This prize provides additional motivation to continue along this research path and to translate our discoveries into novel therapeutic strategies. Only through such efforts can we develop tailored treatments that enhance the resilience of nerve cells to inflammatory stressors and ultimately halt the relentless progression that current therapies cannot fully prevent. I extend my deepest thanks to my lab for their exceptional dedication and outstanding work."
In receiving the Barancik Prize, Friese joins an esteemed group of researchers whose innovation and creativity are accelerating progress toward better treatments and cures for MS. He will be formally honored and deliver the Barancik Prize Lecture at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum on February 6, 2026.
Biosketch: Manuel A. Friese studied medicine at the Universities of Hamburg, Oxford and University College London and received his MD in 2001. He completed neurology training at the Universities of Tübingen and Hamburg, between 2004–2008 he conducted postdoctoral research training at the University of Oxford. He established his laboratory in 2008 at the University Medical Center Hamburg-Eppendorf. He is currently Director of the Center for Molecular Neurobiology, Director of the Institute of Neuroimmunology and Multiple Sclerosis, Professor of Neuroimmunology, and consulting neurologist at the University Medical Centre Hamburg-Eppendorf.
About the Barancik Prize for Innovation in MS Research: This international prize is made possible by the generosity of the Charles and Margery Barancik Foundation. Charles and Margery were two powerful visionaries of the MS movement and a driving force to accelerate pathways to new treatments and ultimately a cure for multiple sclerosis. The Barancik Prize honors researchers who demonstrate exceptional innovation and originality in MS-related science, with a strong emphasis on work that shows clear potential to advance and shape the future of MS research.
# # #
About Multiple Sclerosis
Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.
About the National Multiple Sclerosis Society
The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalmssociety.org, Facebook, X (formerly known as Twitter), Instagram, YouTube or 1-800-344-4867.
END
National Multiple Sclerosis Society awards Dr. Manuel A. Friese the 2025 Barancik Prize for Innovation in MS Research
2026-01-22
ELSE PRESS RELEASES FROM THIS DATE:
PBM profits obscured by mergers and accounting practices, USC Schaeffer white paper shows
2026-01-22
Pharmacy benefit managers (PBMs) under the microscope for their role in high drug prices have often cited their reportedly slim profit margins as evidence that they do not drive up costs. The three leading PBMs, which control about 80% of the prescription drug market, have historically reported profit margins of 4% to 7%, among the lowest in the healthcare industry.
A new white paper from the USC Schaeffer Center for Health Policy & Economics demonstrates that these slim margins are dramatically influenced by the accounting practices PBMs elect to employ. The paper also shows how efforts to assess PBM profits have become more challenging ...
Breath carries clues to gut microbiome health
2026-01-22
The human gut is home to trillions of beneficial microbes that play a crucial role in health. Disruptions in this delicate community of bacteria and viruses — called the gut microbiome — have been linked to obesity, asthma and cancer, among other illnesses. Yet quick diagnostic tools to identify issues within the microbiome that could be addressed to treat these conditions are lacking.
Now, researchers at Washington University School of Medicine in St. Louis and Children’s Hospital of Philadelphia have shown that disease-associated bacteria in the gut can be detected through exhaled breath. They found that chemicals ...
New study links altered cellular states to brain structure
2026-01-22
Researchers at the Icahn School of Medicine at Mount Sinai have characterized how cellular senescence—a biological process in which aging cells change how they function—is associated with human brain structure in both development and late life. The study, published January 22 in Cell, provides new insight into how molecular signatures of cellular senescence that are present during development and aging mirror those associated with brain volume and cortical organization.
Understanding brain structure is a central challenge in neuroscience. Although brain structure changes throughout life and is linked to both aging and neurodegenerative conditions ...
Palaeontology: Ancient giant kangaroos could hop to it when they needed to
2026-01-22
Giant ancestors of modern-day kangaroos — which previous research has estimated could weigh up to 250 kilograms — may have been able to hop in short bursts, according to research published in Scientific Reports. These findings challenge those of previous studies suggesting that giant kangaroos weighing more than 160 kilograms were too heavy for their ankles to withstand hopping.
Megan Jones and colleagues studied the hindlimbs of 94 modern and 40 fossil specimens from 63 kangaroo and wallaby species — including members of the extinct giant kangaroo group Protemnodon, which lived during the Pleistocene (between 2.6 million and 11,700 ...
Decoded: How cancer cells protect themselves from the immune system
2026-01-22
Could this mark a shift in how we think about cancer therapy? At least in the laboratory, evidence suggests it may be. An international research team has succeeded in deciphering a key mechanism that controls the growth of pancreatic cancers. The scientists identified a potential central mechanism by which cancer cells protect themselves from attack by the body's own immune system. Blocking this mechanism resulted in a dramatic reduction in tumours in laboratory animals.
A look at the central driver of cell division
The results of the study have now been published in Cell. The research was primarily carried out by Leonie Uhl, Amel Aziba and ...
ISSCR develops roadmap to accelerate pluripotent stem cell-derived therapies to patients
2026-01-22
The International Society for Stem Cell Research (ISSCR) today announced the upcoming release of “Charting the Translational Pathway: ISSCR Best Practices for the Development of Pluripotent Stem Cell (PSC)-Derived Therapies,” a new paper highlighting some of the most critical aspects of the ISSCR’s breakthrough interactive resource designed to transform how PSC-derived therapies are developed, evaluated, and advanced toward clinical and commercial success. The paper was published today in Stem Cell Reports.
As more than 100 PSC-derived ...
New study shows gut microbiota directly regulates intestinal stem cell aging
2026-01-22
A new study led by Hartmut Geiger at the University of Ulm, Germany, and Yi Zheng and Kodandaramireddy Nalapareddy, Cincinnati Children's Hospital Medical Center (CCHMC), USA reveals that age-related changes in the gut microbiota directly impair intestinal stem cell (ISC) function and that restoring a youthful microbial environment can reverse this decline. The results were published today in Stem Cell Reports.
Cells lining the intestine are constantly renewed to maintain tissue integrity, nutrient absorption, and regenerative capacity following injury. This process ...
Leading cancer deaths in people younger than 50 years
2026-01-22
About The Study: Mortality has decreased for every leading cancer-related death in people younger than 50 years in the U.S. except colorectal cancer, which is now the leading cancer death in females and males combined, up from the fifth-leading cancer death in the early 1990s. Breast cancer and leukemia mortality decreased despite increasing incidence.
Authors: Corresponding Author Rebecca Siegel, MPH, is available for interviews 11 AM-5 PM EST Tuesday, January 20. Senior Author Ahmedin Jemal, DVM, PhD, is ...
Rural hospital bypass by patients with commercial health insurance
2026-01-22
About The Study: Rural hospital bypass (when rural residents receive care at hospitals other than their nearest hospital) rates among commercially insured patients were substantial between 2012 and 2021, generating large payments to receiving hospitals. Relative to Medicare bypass rates, commercial bypass rates were high in this sample. The findings of this study support concerns that commercial bypass contributes to financial distress at rural hospitals.
Corresponding Author: To contact the corresponding author, Caitlin E. Carroll, PhD, email carrollc@umn.edu.
To ...
Jumping giants: Fossils show giant prehistoric kangaroos could still hop
2026-01-22
Scientists studying the fossil remains of giant prehistoric kangaroos have found that even animals weighing more than 200kg may not have been too big to bounce, overturning long-held assumptions about the limits of hopping.
Today, the red kangaroo is the largest living hopping animal and weighs around 90kg. But during the Ice Age, some kangaroos grew more than twice the size of that - some reaching up to 250kg.
For years, researchers believed these giants must have abandoned hopping, as earlier studies suggested that hopping would become mechanically ...